Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.

PloS one - 24 Jan 2007

Sendi Pedram, Günthard Huldrych F, Simcock Mathew, Ledergerber Bruno, Schüpbach Jörg, Battegay Manuel

Abstract excerpt

BACKGROUND: Genotypic antiretroviral resistance testing (GRT) in HIV infection with drug resistant virus is recommended to optimize antiretroviral therapy, in particular in patients with virological failure. We estimated the clinical effect, cost and cost-effectiveness of using GRT as compared to expert opinion in patients with antiretroviral treatment failure. METHODS: We developed a mathematical model of HIV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Health Care Costs

Share to Life Expectancy

Share to Models, Theoretical

Share to Quality of Life

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 17245449
DOI: 10.1371/journal.pone.0000173
PMCID: PMC1769464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.PMID 17245449Read ↗

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.Semantic proximity Read ↗

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.Semantic proximity Read ↗

Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virological failure: A meta-analysis.Semantic proximity Read ↗

A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?Semantic proximity Read ↗

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness analysis of using antiretroviral drug resistance testing.Semantic proximity Read ↗

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.Semantic proximity Read ↗

The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.Semantic proximity Read ↗

Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysisSemantic proximity Read ↗

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.Semantic proximity Read ↗

Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settingsSemantic proximity Read ↗

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.